James Schnell, MD
Gastroenterology · Charleston, SCNPI 1679523070
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 680 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 39 manufacturers reported payments, led by AbbVie at 24.1% of the total. Reporting peaked in 2022 at $2,308 and has fallen 54.2% since, to $1,056 in 2025.
Across 680 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Johnson & Johnson$898
- Gilead$782
- QOL Medical, LLC$687
- Bristol Myers Squibb$511
- plus $5K from 33 others
What the payments were for
- Consulting fees$150%
- Food & beverage$11,677100%
- Education$390%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,731 in reported general payments places this provider in the 85th percentile of 259 gastroenterology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SucraidSacrosidase | 18 | $254,684 |
| LinzessLinaclotide | 222 | $244,068 |
| OcalivaObeticholic Acid | 13 | $120,154 |
| XifaxanRifaximin | 22 | $57,612 |
| CreonLipase/Protease/Amylase | 14 | $32,177 |
| TrulancePlecanatide | 22 | $20,663 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 122 | $19,646 |
| Omeprazole | 550 | $9,690 |
| Esomeprazole Magnesium | 139 | $8,771 |
| Colestipol Hcl | 89 | $6,651 |
| Lubiprostone | 27 | $3,914 |
| Mesalamine | 13 | $3,878 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 48 | $3,133 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 127 | $2,763 |
| Ursodiol | 14 | $1,999 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $2,831 | $276,245236 claims |
| QOL Medical, LLCSucraid | $687 | $254,68418 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $243 | $120,15413 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,486 | $78,27544 claims |
| Braintree Laboratories, Inc.Sutab | $89 | $19,646122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 259 gastroenterology providers in South Carolina.
Other gastroenterology in Charleston
- Erin ForsterCharleston$788K
- Mark DeleggeCharleston$568K
- Nathan ShoresCharleston$217K
- Alejandro SuarezCharleston$210K
- Peter CottonCharleston$193K
- David KochCharleston$48K
- Derek FeussnerCharleston$35K
- Darin DufaultCharleston$33K
- John LitchfieldCharleston$23K
- Michael SagatelianCharleston$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.